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Objective: The purpose of our study was to evaluate the alterations of bone metabolism
and the prevalence of vertebral fractures in the population with HIV and hepatitis B and
C seropositivity in treatment with antiretroviral drugs (HAART).
Methods: We selected 83 patients with diagnosis of HIV, HBV, HCV infection. In all these
patients biochemical examinations of phospho-calcium metabolism and a densitometry
of lumbar spine were performed.We also evaluated lateral spine X-rays in order to analyze
the presence of vertebral deformities and to define their severity. As a control group we
analyzed the prevalence of vertebral fractures in a group of 40 non-infectious patients.
Results: We selected 82 seropositive patients, 46 males and 37 females, with a
median age of 55 ± 10 years. Out of these patients, 55 were infected by HIV, 12
were infected by HBV, 11 presented HIV and HCV co-infection and 4 were HCV+.
The prevalence of hypovitaminosis D in the studied population was 53%, while the
prevalence of osteoporosis and osteopenia was 14 and 48%, respectively. The average
T-score in the fractured population was −1.9 SD. The viral load and the CD4+ cell
count were respectively, directly, and inversely correlated with the number and severity of
vertebral fractures. Antiretroviral therapy regimen containing TDF and PI was a significant
determinant of the presence of vertebral deformities. The use of these drugs was also
associated with lower levels of vitamin D and higher bone turnover levels compared to
other antiretroviral drugs.
Conclusions: HIV patients suffer from bone fragility, particularly at spine, independently
by the level of bone mineral density. In this population, the T-score threshold for the risk of
fracture is higher than that usually used in general population. For this reason, it would be
indicated to perform an X-ray of the spine in order to detect vertebral deformities even in
patients with a normal or slighlty reduced bone mineral density.
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INTRODUCTION
The introduction of antiretroviral therapy (ART) has certainly
improved the prognosis of HIV patients by reducing
their mortality and morbidity, but has also revealed some
complications related to the therapy. Among these, the evidence
of a greater prevalence of reduced Bone Mineral Density
(BMD), osteopenia and osteoporosis in the HIV+ population
than the control population has emerged and has been widely
studied (1–5).
An important meta-analysis of studies comparing BMD
between HIV patients with normal population showed a
prevalence of reduced BMD in 67% of people with HIV and
a prevalence of 15% of osteoporosis in this population (6). A
more recent study shows that even in newly diagnosed, therapy-
naive HIV-infected patients, without any known secondary
causes of osteoporosis, low BMD and high bone resorption are
significantly prevalent (7).
The increased risk of osteopenia/osteoporosis in HIV+
patients is not only due to ART: in these patients there are ART-
related, HIV-related, and even not-HIV not-ART-related risk
factors for bone loss (8, 9). From this, it is clearly demonstrated
that the pathogenesis of reduced bone mass is multifactorial. As
a consequence of reduced BMD, patients with HIV infection are
more likely to present with fragility fractures (10–14).
Nevertheless, data on the prevalence of fragility fractures in
the HIV+ population are poor and often based on retrospective
evaluation of clinical fractures, but this approach dramatically
underestimates the phenomenon (14). Some studies report a
moderate increase in prevalence of fractures in HIV+ patients
compared to the general population, but data are statistically
not significant considering that other risk factors for fractures,
such as low BMI, smoking, and alcohol abuse, show a high
prevalence in these patients (12–16). Other studies, however,
show a significant increased prevalence of fractures, especially
in relation to the high prevalence of frailty (10%, about twice as
much as in the general population) and increased propensity to
fall (16). Comparison of fracture prevalence rates among HIV+
individuals and not-infected individuals in a large US healthcare
system reported a significantly high prevalence of all fractures in
HIV+ males and females (2.87 per 100 infected persons vs. 1.77
per 100 people per year in not-infected persons) in all venues, but
above all to the proximal femur, spine and wrist (14). Subsequent
US studies have confirmed the association between HIV and
increased risk of fractures, including the Veteran Aging Cohort
Study (VACS) and theUSHIVOutpatient Study (HOPS) (17, 18).
In patients with HIV and HCV co-infection, the incidence rate
for all fractures (traumatic and by fragility) varies from 26.8 to
62.3 per 1,000 people per year, while the incidence of fragility
fractures is 2.6 per 1,000 people per year (19, 20). Hepatitis C
co-infection would be, according to these data, an independent
risk factor for fractures along with other documented risk factors:
cigarette smoking, alcohol abuse, advanced age, white race,
low BMI.
According to two Italian studies, data on prevalence of
fractures in the HIV-positive population would be even greater
if we consider the vertebral deformities evaluable with a lateral
spine X-Ray using a semi-quantitative evaluation of vertebral
heights: according to Borderi et al. one HIV+ patient out of
four would have a vertebral fracture and this data would be
of potential clinical relevance, suggesting that bone damage is
much more frequent than previously evaluated found by bone
density evaluation (DXA) (21). The study of Torti et al. shows a
prevalence of fractures in the male HIV+ population 2·5 times
greater than a comparable age control group (22). A more recent
study confirms that the prevalence of asymptomatic vertebral
fractures is high in HIV-infected patients and it is not identified
by the presence of osteoporosis in spine neither predicted by the
FRAX equation (23). A low trabecular bone score (TBS) may be
more associated with vertebral fractures than BMD, according
with another recent Italian study (24).
The results of these studies, therefore, seem to indicate
that lateral spine X-ray plays an important role in screening
osteoporosis in this population, even before or independently
from DXA. In fact, the measurement of bone mineral density
alone cannot exclude the risk of fragility fractures, since many
of these fractures occur in patients with normal BMD, as
seen in other diseases, such as type 1 and 2 diabetes and
acromegaly (25, 26).
The role of ART in increasing the incidence of fractures
has not been completely established: up to now, data seems
to converge on an increased incidence of fractures among
HIV+ patients exposed to therapy than ART-naive patients,
suggesting the role of certain antiretroviral agents, such as
tenofovir disoproxil fumarate (TDF) and protease inhibitors
(PI), in increasing the risk of fractures (27, 28). However,
another recent case-control study does not support these data
and suggests a reduction in the risk of fractures with prolonged
exposure to tenofovir (29). In the light of this, further studies are
needed to evaluate the effect of ART on fracture risk, especially
for those patients who also present other risk factors.
The purpose of our study was to evaluate the alterations
of bone metabolism and the prevalence of vertebral fractures
in a population of patients with HIV and hepatitis B and C
seropositivity in treatment with antiretroviral drugs.
METHODS
A cross-sectional study of 82 patients infected by HIV or
hepatitis B and C was performed. We enrolled both HIV-infected
population and hepatitis-infected population, in order to see if
there were any difference in the phospho-calcium metabolism
and in the prevalence of vertebral fractures between the two
groups. To do so, we considered the two populations to be
comparable both for the inflammatory background and for the
antiretroviral therapy that both groups experienced. A database
was created using data from clinical charts of HIV-infected
patients referring to the skeletal metabolism outpatient clinic of
the Day Hospital of Infectious Diseases and from patients of
the Infectious Diseases Department of Policlinico G.B. Rossi in
Verona from November 2015 to June 2017. Inclusion criteria
in the study were: male and female patients over the age of
40 with a previous or new diagnosis of HIV and/or HBV
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TABLE 1 | Characteristics of the studied population grouped by the presence of
fractures.
Parameter Fractured
mean ± SD
Not fractured
mean ± SD
Age (years) 57 ± 11 53 ± 8
Weight (kg) 66 ± 14 62 ± 12
Height (m) 1.65 ± 1.10 1.63 ± 1.10
Creatinine (mg/dL) 0.83 ± 0.24 0.80 ± 0.17
PTH (pg/mL) 33 ± 19 28 ± 17
Vit.D (ng/mL) 27 ± 7 34 ± 8
Calcium (mg/dL) 9.3 ± 1.2 9.3 ± 1.3
CTX (ng/mL) 0.52 ± 0.38 0.52 ± 0.29
Phosphorus (mg/dL) 3.1 ± 0.6 3.0 ± 0.4
BMD lumbar spine (g/cm2) 0.87 ± 0.11 0.91 ± 0.14
T-score of the lumbar spine −1.9 ± 0.9 −1.5 ± 1.0
Z-score lumbar spine −1.1 ± 1.0 −0.8 ± 1.2
CD 4 (cell/mm3 ) 477 ± 261* 720 ± 174
*p < 0.001.
seropositivity. A minority of patients also had coinfection from
HIV and HCV. For every patients we considered the principal
epidemiological, clinical, immunological and virological risk
factors for osteoporosis: sex, age, race, weight, CD4+ cell count,
HIV viral load, AIDS diagnosis, protease inhibitors and NNRTI
exposure, hepatitis C co-infection, vitamin D deficiency, chronic
renal insufficiency, menopause.
All patients with independent risk factors for impaired
bone metabolism, such as concomitant diseases or infections,
anticonvulsant intake or steroid therapy, kidney failure, and
those who had taken drugs that could affect skeletal metabolism
or bone mass were excluded from the study. Patients with severe
hepatic disease (defined as severe increase in hepatic cytolysis
indices, severe alteration of liver function indices or end-stage
cirrhosis) were also excluded from the study. All the patients had
been supplemented with a single monthly dosage of 100,000 IU
of cholecalciferol before our study.
All patients enrolled in the study performed biochemical
examinations for dosing the following parameters of phospho-
calcium metabolism in serum: 25-OH vitamin D, Creatinine,
Phosphorus (P), Calcium (Ca), Parathyroid hormone (PTH),
C-terminal fragment of type I collagen (s-CTX). Moreover,
calcium excretion was evaluated in urine. In 71 patients, bone
densitometry was performed using DXA (Dual Energy X-Ray
Absorptiometry). In all of patients the lumbar spine densitometry
was performed, considering L1-L4 segment of the lumbar spine.
Given the young age of the patient enrolled, we considered
lumbar densitometry in order to identify the presence of
fractures. Vertebral deformities were detected on lateral spine
X-ray using a semi-quantitative evaluation of vertebral heights
and quantitative morphometric analysis of centrally digitized
images. Fractures have been identified by manual measurement
of 3 vertebral heights (anterior-Ha, middle-Hm, and posterior-
Hp) and height ratios have been calculated (Ha/Hp, Hm/Hp,
Hp/Hp of the upper vertebrae, Hp/Hp of the lower vertebrae).
According to the classification of Genant, we defined the grade
TABLE 2 | Distribution of ART in the population.
Drug Number of treated patients
Tenofovir 36
PI 17
Tenofovir + PI 11
Other drugs 11
ART-naïve 8
of each vertebral fracture, as follows: a decrease of 20–25% has
been considered as a mild deformity (grade 1), of 26–40% as
a moderate one (grade 2) and of >40% as a severe one (grade
3) (30). For each patient, the Spine Deformity Index (SDI) was
calculated by summing the grade of vertebral deformities: SDI
> 1 is indicative of vertebral fracture according to its definition
(reduction in vertebral high of at least 4mm or of 20%). All the
measures were performed by the same physician. For X-rays,
intraobserver agreement were 92.8% (κ= 0.79).
We also analyzed the prevalence of vertebral fractures in
a group of 40 patients referring to the Osteoporosis Clinic
of Internal Medicine of Policlinico G.B. Rossi in Verona,
without HIV, HBV, or HCV infection, comparable to the studied
population by sex, age and average T-score value.
STATISTICAL ANALYSIS
Data were expressed as the mean ± standard deviation.
Difference between groups were assessed by T-student test for
uncoupled data. Frequencies were compared using Chi-square
test, with Fisher correction where appropriate. Logistic regression
models were used in the statistical analysis of factors associated
with the presence of vertebral fractures. ROC analysis was
performed in order to evaluate the best cut-off of DXA expressed
as T-score in terms of sensibility and specificity to predict the
presence of vertebral fractures in this specific setting. Statistical
significance was assumed when P-values were <0.05. Statistical
analysis was carried out using SPSS for Windows version 22.0
(SPSS Inc., Chicago, IL, USA).
RESULTS
We selected 82 seropositive patients, 46 males and 37 females,
with a median age of 55 ± 10 years. The average duration of
the disease from the time of diagnosis in the selected patients
was 17 ± 10 years. Results of anthropometric, biochemical and
densitometric parameters grouped by the presence of fractures
are reported in Table 1. Note that the only significant difference
between the two groups was the CD4 cell count which was lower
in the fractured patients. Out of these patients, 55 were infected
by HIV, 12 were infected by HBV, 11 presented HIV and HCV
co-infection, and 4 were HCV+. Most of the HIV+ and HBV+
patients were experienced to antiretroviral therapy, as showed in
Table 2. The median age of HIV-infected population was 54 ± 9
years and, of these, 29 were males and 26 were females. In HBV-
infected patients the median age was 56± 11 years, 7 were males
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TABLE 3 | Logistic regression evaluating the predictive factors of vertebral fractures.
Variables in the equation
B S.E Wald df Sig. Exp(B) 95% C.I. for Exp(B)
Lower Upper
STEP 1a Age −0.058 0.043 1.827 1 0.176 0.943 0.867 1.027
CD4 cell 0.004 0.002 4.585 1 0.032 1.004 1.000 1.008
Viralload −0.002 0.008 0.086 1 0.769 0.998 0.982 1.014
Creatinine −2.006 1.951 1.056 1 0.304 0.135 0.003 6.165
PTH −0.012 0.030 0.157 1 0.692 0.988 0.932 1.048
Vit.D 0.032 0.035 0.808 1 0.369 1.032 0.963 1.106
Calcium 0.741 1.162 0.407 1 0.524 2.098 0.215 20.472
BMD lumbar spine 2.279 8.244 0.076 1 0.782 9.764 0.000 101595310
T-score lumbar spine −0.194 0.870 0.049 1 0.824 0.824 0.150 4.536
Constant −7.493 12.375 0.367 1 0.545 0.001
aVariable(s) entered on step 1:age, CD4 cell, vialload, creatinine, PTH, vit.D, calcium, BMD lumbar spine, T-score lumbar spine.
Note that CD4 count was the main determinant after the correction for age, viral load, cretinine and the bone metabolism parameters.
and 5 females. The median age of HIV/HCV-positive people was
51 ± 4 years, 9 males and 2 females. The last group of HCV+
patients was composed of 1 male and 3 females, whose median
age was 63± 10 years.
No statistical differences in the main parameters of phospho-
calcium metabolism have been detected between population
infected by HIV and population infected by hepatitis viruses
(HBV and HCV).
All of patients have been supplemented with cholecalciferol
before our study with a single monthly dose of 100.000 IU;
despite this, the median levels of vitamin D in the population
were under the normal range (28.7± 14.4 ng/ml).
Analyzing data from densitometry, osteoporosis was present
only in 17% of the population, osteopenia in 56.3%, while
normal bone mass was present in 26.7% of the population.
The prevalence of fractures was high: 34 patients presented at
least one vertebral deformity (41% of the population). People
with vertebral fractures were significantly older (>60 years old)
and fractures were also more severe in older population than
in younger population (p < 0.001). In the group of patients
treated with bone-affecting drugs (tenofovir, protease inhibitors
or a combination of them), the mean number of fractures was
significantly higher than in the group who didn’t receive these
drugs (1.4 ± 0.9 vs. 0.7 ± 0.5, p < 0.05). Similarly, the median
SDI (Spine Deformity Index) was higher in the first group than
in the second one (2.2 ± 1.1 vs. 0.86 ± 1.00, p < 0.05). Of the
fractured patients, 44% (15 patients) had grade 1 fractures, 41%
(14 patients) had grade 2 fractures and 15% (5 patients) had
grade 3 fractures. Multiple vertebral fractures were present in 25
patients (30.4%).
By the logistic regression considering the presence of
fractures, the CD4+ cell count emerged as a predictive factor
of the presence of fractures, after correction for bone mass,
age, vitamin D levels and other parameters of phospho-calcium
metabolism (Table 3). CD4+ cell count negatively correlated
with the number of fractures and also with SDI (Spine Deformity
Index) (p < 0.01 and R2 = −0.41). The viral load directly
correlated with the presence and the severity of fractures (p <
0.001 and R2 < 0.45). It also directly correlated with PTH levels
and negatively correlated with vitamin D levels. Furthermore,
there was a negative correlation between CD4+ cell count and
the viral load.
The mean T-score in patients with fractures was −1.9 ± 0.9
and the mean Z-score was−1.1± 1.2, while the mean T-score in
patients without any fracture was−1.5± 0.8 without statistically
significant differences between the two groups. Bone Mass
Density (BMD) didn’t correlate with the presence of fractures.
To better evaluate the relationship between bone density
and presence of vertebral fracture in this specific setting, we
performed ROC analysis using lumbar spine T-score as test
variable. The AUC for this diagnostic tool in this setting was 0.68
and the best cut-off was 1.7 SD showing 73% of sensitivity and
41% of specificity with a Yourden’s index of 0.32 (Figure 1).
Analyzing the main parameters of phospho-calcium
metabolism, resorption marker (sCTX) in the group of
patients receiving drugs inducing bone loss was significantly
higher than that of patients who did not receive these drugs (0.52
± 0.31 vs. 0.30± 0.08, p < 0.001) (Figure 2).
Finally, comparing the population with HIV+HCV+ co-
infection with the population with only HIV+ infection
(Table 4), the mean T-score was significantly lower in the first
group than in the second one (−2.2 ± 0.8 vs. −1.6 ± 1.2) (p <
0.05). Furthermore, fractures were more severe in the first group
than in the second one, since SDI was significantly higher in the
HIV+HCV+ co-infected population (2.4 ± 2.0 vs. 1.7 ± 1.0)
(Figure 3). Most of the fractures (about 60%) were dorsal, with
a wedge morphology and of grade 2.
We also analyzed the prevalence of vertebral fractures in
a group of 40 patients referring to the Osteoporosis Clinic
of Internal Medicine of Policlinico G.B. Rossi in Verona,
without HIV, HBV or HCV infection, comparable to the
studied population by sex, age and average T-score value.
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FIGURE 1 | The ROC analysis between bone density and presence of
vertebral fracture. The AUC for this diagnostic tool in this setting was 0.68 and
the best cut-of was 1.7 SD showing 73% of sensitivity and 41% of specificity.
FIGURE 2 | Bone resorption marker (CTX) was significantly higher in patients
treated with bone-affecting drugs compared to bone-sparing drugs treated
patients (*p < 0.001).
The main characteristics of the non-infectious group are
described in Supplemental Table 1. The prevalence of fractures
in these patients was significantly lower than that of the study
population (17%).
DISCUSSION
Comparing the HIV-infected population and the hepatitis-
infected population, no statistical differences were found in the
main parameters of phosphocalcic metabolism, suggesting a
similar bone disease in these patients.
TABLE 4 | Differences between HIV and HIV + HCV population in parameters of
phospho-calcic metabolism, features, and bone densitometry value.
HIV (n◦55)
mean±SD
HIV/HCV (n◦11)
mean ± SD
Age (years) 54 ± 9 51 ± 4
PTH (pg/mL) 31 ± 14 24 ± 15
Vit. D (ng/mL) 28 ± 8 28 ± 10
Calcium (mg/dL) 9.3 ± 0.3 9.2 ± 0.4
CTX (ng/mL) 0.54 ± 0.34 0.36 ± 0.20
Phosphorus (mg/dL) 3.0 ± 0.5 3.1 ± 0.5
BMD lumbar spine (g/cm2) 0.91 ± 0.13 0.84 ± 0.10
T-score of the lumbar spine (SD) −1.7 ± 0.2 −2.0 ± 0.8
FIGURE 3 | The severity of fractures was higher in HIV+HCV co-infected
population compared to HIV-infected population (*p < 0.05).
Our study showed a very high prevalence of vertebral fractures
in patients infected by HIV and hepatitis viruses: the 41% of
the studied population showed at least one vertebral deformity.
Despite the high prevalence of fractures, osteoporosis was present
only in the 17% of the population enrolled in the study, while
most of the population had a normal or a slightly reduced bone
mass. In fact, the average T-score in fractured patients was −1.9
SD and the average Z-score −1.1 SD and these data were not
statistically different from T-score measured in the non-fractured
population (−1.5 SD). This means that bone mineral density
could not be the best predictor of the risk of fragility fractures
in these individuals and that a lateral X-rays at the spine could
play an important role in detecting patients at a high risk of
fracture even when DXA scan shows a normal BMD (22–24).
In other words, these patients may experience vertebral fractures
even when T-score levels are in the normal range. For this reason,
in this population, it may be useful to define a threshold of
fracture risk expressed in terms of T-score less negative than that
traditionally considered for the general population. In our study,
this T-score threshold was −1.7 SD, as expressed by ROC curve.
In patients with T-score equal to or less than the proposed cut-
off, it would be indicated to perform a radiographic study of the
dorso-lumbar spine in latero-lateral projection in order to verify
the presence of vertebral deformities and, where present, to define
their severity.
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In addition, bone mass levels correlated negatively with age:
in older patients there were bone mineral density levels that were
worse than in younger patients. Themost plausible interpretation
of this data might be that, on the one hand, age represents
an independent risk factor for osteoporosis even in the general
population, on the other hand, depending on the onset of the
disease, elderly HIV patients may have suffered for more time
the adverse effects of antiretroviral therapy, as many studies
show (31–34).
Our study suggested that there could be some other predictors
of risk fractures in this specific population, such as infection-
related factors: CD4+ cell count and the viral load. Indeed, we
found a direct correlation between the HIV viremia and the
number and the severity of fractures and, on the other hand, an
inverse correlation between CD4+ cell count and the number
of fractures. These data confirm an increased fracture rate in
individuals with worse indices of infection, as other studies
have suggested (31, 32). HIV and Hepatitis C co-infection have
consistently been reported to be associated with an increased
fracture risk: in our study, the bone mass was significantly lower
in individuals with HIV andHCV co-infection and the severity of
fractures was, consequently, greater than that of the population
with only HIV infection (20, 31). Hepatitis C co-infection was
confirmed to be an independent predictor of incident fracture
and this is probably explained by the effect of chronic liver disease
present in these patients (19, 35).
Furthermore, we investigated the impact of antiretroviral
therapy on the bone metabolism and also on the fracture risk.
We compared the effect on bone metabolism of drugs recognized
by the literature as mainly affecting the bone, i.e., tenofovir (TDF)
and protease inhibitors (PI), with other drugs that did not appear
to have this effect (32–35). We observed a significant increase
in plasma CTX levels in the first group compared to the second
group. Therefore, an antiretroviral therapy regimen that includes
these drugs seems to increase bone resorption markers. Besides,
patients in therapy with TDF and PI showed an increased fracture
risk, since the average number of fractures as well as their degree
of severity (SDI) were higher in this group of individuals than in
the group who was not treated with such drugs.
Another interesting aspect in the use of antiretroviral
therapy concerns the way it alters vitamin D metabolism
lowering vitamin D levels in the blood (36–38) From the
biochemical analyses of the patients, we found that the
average levels of vitamin D were 28.7 ± 14.4 ng/ml and the
prevalence of hypovitaminosis D was 53%, although all patients
underwent supplementation with cholecalciferol before our
study. Interestingly, a high viral load was associated with lower
vitamin D levels: this could suggest that individuals with a
worse progression of the disease have an impaired vitamin D
metabolism. Furthermore, low levels of vitamin D in the blood
have been correlated with an increased risk of vertebral fractures
in HIV-infected patients, as some studies show (39). These
findings, in line with what is reported in the literature, confirm
the hypothesis that vitamin D metabolism is probably altered in
these patients and that the normalization of 25-OH-D levels is
achievable with higher doses of cholecalciferol than those usually
used in the general population (40).
A limitation of the study is that this is a cross-sectional
study, since we didn’t take into account the duration of
disease or even the duration of antiretroviral therapy in
the patients considered. Furthermore, for some subgroups of
patients, such as people with HIV and HCV coinfection or
the HCV infected patients, the number of the population
was significantly lower than the population of HIV infected
patients. Another limit of the study is the lack of a control
group. However, we compared the results from this study
with those obtained from a population without HIV, HBV,
HCV seropositivity matched by age, sex, and T-score value
and we found that in these patients the prevalence of
fractures was significantly lower than that of the studied
population (17%).
CONCLUSION
Adults with HIV, HBV, and HCV infection have an increased
fracture risk compared to the general population age-matched,
which is associated to an increased bone turnover due to the
underlying disease and the antiretroviral therapy (ART). The
role of antiretroviral treatment in genesis and maintenance of
hypovitaminosis D and in the increase in skeletal turnover is
also confirmed. A better control of the disease activity seems to
be the first goal to reduce the impact on bone caused by the
inflammatory background in these patients. On the other hand,
the ART itself could lead to a worse outcome of bone metabolism
as well as increased fracture risk.
The best approach to these patients should provide a detailed
assessment of the parameters of bone metabolism including bone
turnover markers. In addition, densitometry (DXA) is confirmed
to be a useful tool for assessing possible bone mineral density
impairment, although, in this particular setting, even moderately
reduced bone mass levels may be associated with increased
fracture risk. For this reason it should be necessary to define a
different T-score threshold associated with an increased fracture
risk. Consequently, in these patients it could be important to
perform radiographs of the dorso-lumbar spine in order to detect
vertebral fractures even in patients with a normal or slightly
reduced bone mass.
The early detection of patients at a high risk of fractures
allow to introduce a bone sparing treatment already in the
first phases of the disease, by using wherever possible a low-
impact antiretroviral therapy and by monitoring the presence of
vertebral fractures.
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